Choice Institutional Equities issued a buy rating for Park Medi World with a target price of Rs 350. The firm expects growth from a 6,590-bed pipeline operational by December 2028. Despite temporary cost pressures, analysts believe the hospital chain is well-positioned for long-term success through its disciplined expansion and specialty mix.
Choice Institutional Equities's report on Park Medi World Growth visibility supported by disciplined expansion and improving business mix: PARKHOSP remains well-positioned for a sustained longterm growth, underpinned by its 6,590-bed pipeline to be operational by December 2028. Additional growth drivers include its cluster-led expansion strategy, improving specialty mix, gradual shift towards a higher private-pay payer mix and healthy ARPOB growth. While the near-term margin is negatively impacted by new hospital ramp-up and one-off cost pressure, we expect these transitory headwinds to normalise over the next few quarters.
Further, the recently-announced oncology drug trade-margin cap is anticipated to have a negligible impact on profitability. We forecast Revenue/EBITDA/PAT to expand at a CAGR of 28.0%/28.0%/31.4% over FY26-29E. Outlook Rolling forward our valuation to 18x average FY28-FY29E EV/EBITDA, we retain our 'BUY' rating with a target price of INR 350. For all recommendations report, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
